

# Lucienne Costa-Frossard França

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5512206/publications.pdf>

Version: 2024-02-01

49  
papers

791  
citations

516710

16  
h-index

552781

26  
g-index

61  
all docs

61  
docs citations

61  
times ranked

1303  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103669.	2.0	4
2	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. <i>Frontiers in Immunology</i> , 2022, 13, 842354.	4.8	1
3	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103805.	2.0	2
4	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage. <i>Clinical and Translational Medicine</i> , 2022, 12, e837.	4.0	4
5	Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study. <i>Neurology and Therapy</i> , 2022, 11, 1101-1116.	3.2	3
6	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 743.	2.5	6
7	Non-severe immunosuppression might be associated with a lower risk of moderate-severe acute respiratory distress syndrome in COVID-19: A pilot study. <i>Journal of Medical Virology</i> , 2021, 93, 2243-2251.	5.0	8
8	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 761-769.	2.9	40
9	The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19. <i>Journal of Clinical Immunology</i> , 2021, 41, 315-323.	3.8	16
10	Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis. <i>Brain and Behavior</i> , 2021, 11, e02044.	2.2	2
11	Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. <i>Cells</i> , 2021, 10, 119.	4.1	12
12	Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102747.	2.0	4
13	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment. <i>Scientific Reports</i> , 2021, 11, 9299.	3.3	6
14	Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 713-719.	1.8	8
15	Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102860.	2.0	10
16	Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. <i>Neurodegenerative Disease Management</i> , 2021, 11, 251-261.	2.2	5
17	SARS-CoV-2 Infection in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	27
18	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 685139.	4.8	13

#	ARTICLE	IF	CITATIONS
19	Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	20
20	Quantifying the patient's perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire. <i>PLoS ONE</i> , 2021, 16, e0255317.	2.5	0
21	Risk and outcomes of COVID-19 in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 3712-3721.	3.3	26
22	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	15
23	Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology. <i>Frontiers in Neurology</i> , 2021, 12, 722801.	2.4	11
24	Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	38
25	Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118844.	0.6	0
26	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. <i>Frontiers in Immunology</i> , 2021, 12, 760546.	4.8	3
27	Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression. <i>Frontiers in Immunology</i> , 2021, 12, 798003.	4.8	3
28	Real-life clinical practice studies in multiple sclerosis. <i>Farmacia Hospitalaria</i> , 2021, 45, 51-52.	0.6	0
29	Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study. <i>CNS Drugs</i> , 2020, 34, 1275-1286.	5.9	6
30	Whole-Transcriptome Analysis in Peripheral Blood Mononuclear Cells from Patients with Lipid-Specific Oligoclonal IgM Band Characterization Reveals Two Circular RNAs and Two Linear RNAs as Biomarkers of Highly Active Disease. <i>Biomedicines</i> , 2020, 8, 540.	3.2	8
31	Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. <i>Scientific Reports</i> , 2020, 10, 14244.	3.3	12
32	Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. <i>Journal of Neurology</i> , 2020, 267, 2362-2371.	3.6	21
33	The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms. <i>Frontiers in Neurology</i> , 2020, 11, 152.	2.4	21
34	Acetate correlates with disability and immune response in multiple sclerosis. <i>PeerJ</i> , 2020, 8, e10220.	2.0	23
35	Factors associated with dimethyl fumarate-induced lymphopenia. <i>Journal of the Neurological Sciences</i> , 2019, 398, 4-8.	0.6	29
36	Perception of stigma in patients with primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731985271.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 355-363.	3.7	21
38	Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1317-1327.	3.0	49
39	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. <i>Journal of Neurology</i> , 2018, 265, 24-31.	3.6	11
40	Does normal substantia nigra echogenicity make a difference in Parkinson's disease diagnosis? A real clinical practice follow-up study. <i>Journal of Neurology</i> , 2018, 265, 2363-2369.	3.6	5
41	Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 360, 41-44.	0.6	16
42	Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 138-139.	0.5	5
43	Lipid-specific immunoglobulin G bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015, 77, 447-457.	5.3	48
44	Comparative Diagnostic Accuracy of Ganglion Cell-Inner Plexiform and Retinal Nerve Fiber Layer Thickness Measures by Cirrus and Spectralis Optical Coherence Tomography in Relapsing-Remitting Multiple Sclerosis. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	61
45	Color-Code Agreement Among Stratus, Cirrus, and Spectralis Optical Coherence Tomography in Relapsing-Remitting Multiple Sclerosis With and Without Prior Optic Neuritis. <i>American Journal of Ophthalmology</i> , 2013, 155, 890-897.e2.	3.3	23
46	High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. <i>Clinica Chimica Acta</i> , 2012, 413, 1813-1816.	1.1	54
47	Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis. <i>Archives of Neurology</i> , 2012, 69, 191.	4.5	46
48	Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2011, 17, 690-694.	3.0	25
49	Importance of age at diagnosis in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 341-342.	2.8	2